The challenge of follow-on biologics for treatment of multiple sclerosis

S. C. Reingold, J. P. Steiner, C. H. Polman, J. A. Cohen, M. S. Freedman, L. Kappos, A. J. Thompson, J. S. Wolinsky

Research output: Contribution to journalArticle


Intellectual property protections for biologic medicinals for multiple sclerosis (MS) are beginning to expire, opening the possibility of development, regulatory approval, and marketing of so-called follow-on biologics, biosimilars, or subsequent entry biologics that might be offered at lower price to consumers and third-party payers, as has been the case for generic drugs. Determining the comparability of a follow-on biologic to its innovator product is more difficult than for small-molecule drugs because of the greater complexity of biologics and the possibility that manufacturing differences can introduce differences in biologic activity and immunogenicity that could result in unpredictable differences in safety or efficacy. We provide a perspective on issues surrounding development, regulatory approval, and potential use of follow-on biologics, with an emphasis on disease-modifying agents for MS.

Original languageEnglish (US)
Pages (from-to)552-559
Number of pages8
Issue number7
StatePublished - Aug 18 2009

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'The challenge of follow-on biologics for treatment of multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Reingold, S. C., Steiner, J. P., Polman, C. H., Cohen, J. A., Freedman, M. S., Kappos, L., Thompson, A. J., & Wolinsky, J. S. (2009). The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology, 73(7), 552-559.